Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of
1934
Date of Report (Date of earliest event
reported): February 18,
2009
MICROMET,
INC.
(Exact Name of Registrant as Specified in
its Charter)
|
Delaware
|
0-50440
|
52-2243564
|
|
(State or Other
Jurisdiction
|
(Commission
|
(IRS
Employer
|
|
of
Incorporation)
|
File
Number)
|
Identification
No.)
|
|
|
|
|
6707
Democracy Boulevard, Suite 505, Bethesda, MD
|
20817
|
|
(Address of Principal Executive
Offices)
|
(Zip
Code)
|
Registrant’s telephone number, including area code:
(240)
752-1420
(Former Name or Former Address, if
Changed Since Last
Report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2.
below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Effective
as of February 18, 2009, the Board of Directors (the “Board”) of Micromet, Inc.
(the “Company”), acting upon the recommendation of the Nominating/Corporate
Governance Committee of the Board, appointed Dr. Kapil Dhingra as a member of
the Board. Dr. Dhingra will fill the vacancy on the Board resulting from the
resignation of Barclay Phillips in September 2008 when Mr. Phillips joined the
Company as its Senior Vice President and Chief Financial Officer.
There is
no arrangement or understanding between Dr. Dhingra and any other person
pursuant to which he was selected as a director. Dr. Dhingra’s
initial term as a director of the Company will extend until the 2010 annual
meeting of stockholders of the Company. Pursuant to the director
compensation policy of the Company, Dr. Dhingra was granted a stock option for
35,000 shares of common stock.
Dr.
Dhingra, age 49, is the sole member of KAPital Consulting, LLC,
a consulting company dedicated to assisting biotechnology,
pharmaceutical and diagnostic companies realize clinical and commercial advances
in oncology, that he founded in June 2008. From 1999 to June 2008,
Dr. Dhingra worked in positions of increasing responsibility at Hoffman-La
Roche, most recently serving as Vice President, Head, Oncology Disease Biology
Leadership Team, and Head, Oncology Clinical Development. Prior to
Hoffmann-La Roche, from 1996 to 1999, Dr. Dhingra worked as a Clinical and
Senior Clinical Research Physician with Eli Lilly and Company, and from 1989 to
1996, a Clinical Instructor, Assistant Professor of Medicine (tenure-track) at
the University of Texas M.D. Anderson Cancer Center. Throughout his
industry career, he maintained an active faculty appointment, initially at
Indiana University School of Medicine from 1997 to 1999 as Clinical Associate
Professor, and, more recently, at Memorial Sloan Kettering Cancer Center in New
York from 2000 to 2008. Dr. Dhingra holds an M.B., B.S. degree
(equivalent to a US M.D. degree) from the All India Institute of Medical
Services, and has performed postgraduate work the All India Institute of Medical
Services, the Lincoln Medical and Mental Health Center (New York Medical
College), Bronx, NY and Emory University School of Medicine, Atlanta,
GA.
Item
8.01. Other Events.
On
February 23, 2009, the Company issued a press release announcing the appointment
of Kapil Dhingra to the Board, a copy of which is attached hereto as Exhibit
99.1.
Item 9.01. Financial Statements
and Exhibits.
| |
Exhibit
No.
|
Description
|
| |
|
|
|
|
99.1
|
Press
Release dated February 23,
2009
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
MICROMET,
INC.
|
|
| |
|
|
|
| |
|
|
|
|
|
By:
|
/s/ Matthias
Alder |
|
| |
|
Name: Matthias
Alder
|
|
| |
|
Title:
Senior Vice President & General
Counsel
|
|
| |
|
|
|
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
| |
|
|
99.1
|
Press
Release dated February 23,
2009
|